Additional file 1: Figure S1. of PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

PD-L1 was upregulated in SNK-6 cells through MAPK/NF-κB pathway. (A) The expression level of p-Raf-B, Raf-B, p-p38, p38, p-JNK, JNK, p-ERK, ERK, p65, and PD-L1 in SNK-6 cells or SNK-6 cells treated with 0.1 μM SB590885, a selective B-Raf inhibitor for 1 h. (B) The expression level of p-ERK, ERK, p65, and PD-L1 in SNK-6 cells or SNK-6 cells treated with 20 μM PD98059, a selective ERK inhibitor for 1 h. (C) The expression level of p-p38, p38, p65, and PD-L1 in SNK-6 cells or SNK-6 cells treated with 10 μM SB203580, a selective p38 inhibitor for 1 h. (D) The expression level of p-JNK, JNK, p65, and PD-L1 in SNK-6 cells or SNK-6 cells treated with 20 μM SP600125, a selective JNK inhibitor for 1 h. (E) The expression level of p65 and PD-L1 in SNK-6 cells or SNK-6 cells treated with 100 μM pyrrolidine dithiocarbamate (PDTC), a selective inhibitor of NF-κB for 1 h. (TIF 1305 kb)